Phase 2 Study of Solbinsiran Injections to Lower Triglycerides in Adults with Severe Hypertriglyceridemia

What this Trial Is About

Researchers are evaluating the safety and effectiveness of solbinsiran compared to a placebo in adults with severe hypertriglyceridemia, a condition involving very high triglyceride levels. This Phase 2, randomized, double-blind, placebo-controlled study aims to understand how solbinsiran affects triglycerides and other lipid measures. The study focuses on participants with fasting triglyceride levels of 500 mgdL or higher. Participants will be randomly assigned to receive either solbinsiran or a placebo through two subcutaneous injections. The study uses a parallel design, meaning participants receive only one of the two treatments. The trial will last at least 24 weeks, with assessments occurring from baseline through weeks 16 to 24 to measure changes in triglycerides and other lipids. During the study, participants will undergo evaluations of lipid levels including triglycerides, Angiopoietin-like-3, very-low-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol. Pharmacokinetic assessments will be done to measure the drug concentration over time. Safety and efficacy will be monitored throughout the trial, which is expected to complete in August 2027.

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia